Ute Dugan

1.1k total citations
17 papers, 248 citations indexed

About

Ute Dugan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ute Dugan has authored 17 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ute Dugan's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ute Dugan is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ute Dugan collaborates with scholars based in United States, Eswatini and Germany. Ute Dugan's co-authors include Kenneth Kolinsky, Larry Norton, Clifford A. Hudis, Maria Theodoulou, Tiffany A. Traina, Kathryn Packman, Brian Higgins, David Heimbrook, Kimberly Feigin and Sujata Patil and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ute Dugan

16 papers receiving 238 citations

Peers

Countries citing papers authored by Ute Dugan

Since Specialization

Citations

This map shows the geographic impact of Ute Dugan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Dugan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Dugan more than expected).

Fields of papers citing papers by Ute Dugan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Dugan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Dugan. The network helps show where Ute Dugan may publish in the future.

Co-authorship network of co-authors of Ute Dugan

This figure shows the co-authorship network connecting the top 25 collaborators of Ute Dugan. A scholar is included among the top collaborators of Ute Dugan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ute Dugan. Ute Dugan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials 2025 ·Journal for ImmunoTherapy of Cancer ·Christopher R. Cabanski, Enjun Yang, Mark Stewart, Jeff Allen, John E. Connolly, Ute Dugan, Philip D. Greenberg, Crystal L. Mackall, Carl H. June, (unknown), Marcela V. Maus, Antoni Ribas	0
2	Abstract CT138: Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort 2024 ·Cancer Research ·Apostolia M. Tsimberidou, Alexandra Drakaki, Danny N. Khalil, Kwame Okrah, Mike Schachter, (unknown), Diane M. Da Silva, (unknown), Christine N. Spencer, Wai Chin Foo, Matthew Adamow, Phillip Wong, Justin Fairchild, Jamie Arnott, Ute Dugan, Silvia Boffo, Lisa Salvador, Christopher R. Cabanski, Sumit K. Subudhi, Padmanee Sharma	1
3	765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial 2023 ·SHILAP Revista de lepidopterología ·Eileen M. O’Reilly, Mark H. O’Hara, George A. Fisher, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, Jamie Arnott, Christopher R. Cabanski, Samik Upadhaya, (unknown), Jay R. Campbell, (unknown), Oliver Rosen, Samantha Bucktrout, Silvia Boffo, Ute Dugan, Jill O’Donnell-Tormey, Robert H. Vonderheide, Danny N. Khalil	1
4	An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. 2021 ·Journal of Clinical Oncology ·Apostolia M. Tsimberidou, Alexandra Drakaki, Danny N. Khalil, Shivaani Kummar, F. Stephen Hodi, David Y. Oh, Christopher R. Cabanski, (unknown), Theresa LaVallee, Marko Spasić, (unknown), (unknown), Nicholas Bayless, Cheryl Selinsky, (unknown), Jill O’Donnell-Tormey, Vanessa M. Hubbard-Lucey, Ute Dugan, James P. Allison, Padmanee Sharma	1
5	Multisector Collaborations and Global Oncology: The Only Way Forward 2021 ·JCO Global Oncology ·Charmaine Blanchard, (unknown), (unknown), (unknown), Susan Msadabwe, Michael Mwachiro, Cyprien Shyirambere, (unknown), Danny A. Milner, Katherine Van Loon, Rebecca DeBoer, (unknown), Ute Dugan, Ellen Baker, Lawrence N. Shulman	8
6	Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients 2019 ·Clinical Trials ·Mark H. O’Hara, Eileen M. O’Reilly, Rosemarie Mick, Gauri R. Varadhachary, Zev A. Wainberg, Andrew H. Ko, George A. Fisher, Osama E. Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Erica L. Carpenter, (unknown), Pier Federico Gherardini, Lacey Kitch, Cheryl Selinsky, Theresa LaVallee, Ovid Trifan, Ute Dugan, Vanessa M. Hubbard-Lucey, Robert H. Vonderheide	13
7	Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients 2019 ·Cancer Research ·Mark H. O’Hara, Eileen M. O’Reilly, Rosemarie Mick, Gauri R. Varadhachary, Zev A. Wainberg, Andrew H. Ko, George A. Fisher, Osama E. Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Erica L. Carpenter, (unknown), Pier Federico Gherardini, (unknown), Cheryl Selinsky, Theresa LaVallee, Ovid Trifan, Ute Dugan, Vanessa M. Hubbard-Lucey, Robert H. Vonderheide	55
8	Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical Modeling 2010 ·Breast Disease ·Tiffany A. Traina, Ute Dugan, Brian Higgins, Kenneth Kolinsky, Maria Theodoulou, Clifford A. Hudis, Larry Norton	27
9	A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. 2009 ·Cancer Research ·(unknown), Maria Theodoulou, Ute Dugan, (unknown), Shekhar Patil, (unknown), Lisa Godfrey, Larry Norton, Clifford A. Hudis	5
10	Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. 2009 ·PubMed ·Kenneth Kolinsky, Yue Zhang, Ute Dugan, David Heimbrook, Kathryn Packman, Brian Higgins	16
11	In vivoactivity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models 2009 ·Molecular Cancer Therapeutics ·Kenneth Kolinsky, Ben‐Quan Shen, Yue Zhang, Joseph D. Kohles, Ute Dugan, Thomas F. Zioncheck, David Heimbrook, Kathryn Packman, Brian Higgins	34
12	A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), Ute Dugan, Kimberly Feigin, Shekhar Patil, (unknown), Larry Norton, C. Hudis	6
13	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer 2008 ·Journal of Clinical Oncology ·Tiffany A. Traina, Maria Theodoulou, Kimberly Feigin, Sujata Patil, (unknown), (unknown), Ute Dugan, Larry Norton, Clifford A. Hudis	52
14	Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling 2007 ·Journal of Clinical Oncology ·Maria Theodoulou, (unknown), Ute Dugan, Diana Lake, Monica Fornier, (unknown), Sujata Patil, (unknown), Larry Norton, Clifford A. Hudis	2
15	2012 POSTER Activity of capecitabine (C) and docetaxel (D) doublets with and without trastuzumab (T) in a breast cancer xenograft model 2007 ·European Journal of Cancer Supplements ·(unknown), Kenneth Kolinsky, (unknown), Ute Dugan, (unknown), Brian P. Higgins	1
16	Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model 2007 ·Journal of Clinical Oncology ·Tiffany A. Traina, Brian Higgins, Maria Theodoulou, Ute Dugan, Kenneth Kolinsky, (unknown), David Heimbrook, Kathryn Packman, Clifford A. Hudis, Larry Norton	5
17	Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. 2007 ·PubMed ·Brian Higgins, Kenneth Kolinsky, Michael Linn, (unknown), Yue Zhang, (unknown), Ute Dugan, David Heimbrook, Kathryn Packman	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact